2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
4,96%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 53 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 27 | - | - |
Ylin
467,5VWAP
Alin
459,4VaihtoMäärä
50,4 108 713
VWAP
Ylin
467,5Alin
459,4VaihtoMäärä
50,4 108 713
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenColoplast is a quality stock with high margins but also a very high PE, which demands high growth.. A growth they haven't exactly had, and not least, they have faced particularly challenging conditions in the Chinese market. Conversely, demographics work for them. The world's population is getting older. This increases the need for: catheters ostomy products wound care This provides (should provide) long-term structural growth. So more than tempting to start buying up, the dividend is 5 pct., but it is certainly not cheap on key figures despite a loooong and significant share price drop.- ·5 t sittenIs it conceivable Coloplast will cut the dividend?
- ·6 t sittencouldn't really detect much enthusiasm???
·6 t sittenChatGPT: Gavin Wood Gavin Wood is a Canadian business leader in the global medical technology industry (medtech). He has been appointed as the new Chief Executive Officer (CEO) of the Danish company Coloplast, where he will take office in 2026. His career has primarily been in international health and medical technology groups, where he has worked with strategic management, commercial development, and global expansion. ⸻ Background and Education Wood is educated in both law and business: • Bachelor of Laws from Carleton University in Ottawa • MBA from Queen’s University The combination of legal and commercial education is relatively common among leaders in regulated industries such as medtech and pharma, where an understanding of regulatory requirements, healthcare systems, and global markets is important. ⸻ Career in the Medtech Industry Wood has worked for more than two decades in the international health industry. A large part of his career has been with Johnson & Johnson, one of the world's largest healthcare groups. Johnson & Johnson MedTech At Johnson & Johnson, he held a number of leadership roles, including: • Head of the MedTech business in Europe, Middle East, and Africa (EMEA) • Responsibility for large portfolios within surgery and medical devices • Leadership of organizations with thousands of employees across many countries Hem also worked in the Ethicon division, which produces surgical instruments, sutures, and robotic technology for operations. Mölnlycke Health Care Before some of his later roles at Johnson & Johnson, he was also a leader at Mölnlycke Health Care, a Swedish company known for wound care products and surgical equipment. Here he worked with international commercial development and market strategy. ⸻ Role in the Industry In addition to his corporate roles, Wood has also had influence in the industry through the organization MedTech Europe, where he has served as Vice-Chairman. The organization represents European manufacturers of medical devices and works with regulation, innovation, and health policy in the EU. ⸻ CEO for Coloplast When he was chosen as CEO for Coloplast, the board pointed to several reasons: • Extensive international experience in medical technology • Proven ability to drive global growth and commercial scaling • Experience with both hospital technology and chronic patient products Coloplast is a global company that produces products for, among others: • ostomy • continence • wound care • urology The company has its headquarters in Denmark, but the majority of its revenue comes from international markets. Wood is therefore expected to: • strengthen Coloplast's global growth, especially in the USA • develop new medical products and technologies • continue the company's focus on specialized patient groups
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
4,96%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenColoplast is a quality stock with high margins but also a very high PE, which demands high growth.. A growth they haven't exactly had, and not least, they have faced particularly challenging conditions in the Chinese market. Conversely, demographics work for them. The world's population is getting older. This increases the need for: catheters ostomy products wound care This provides (should provide) long-term structural growth. So more than tempting to start buying up, the dividend is 5 pct., but it is certainly not cheap on key figures despite a loooong and significant share price drop.
- ·5 t sittenIs it conceivable Coloplast will cut the dividend?
- ·6 t sittencouldn't really detect much enthusiasm???
- ·6 t sittenChatGPT: Gavin Wood Gavin Wood is a Canadian business leader in the global medical technology industry (medtech). He has been appointed as the new Chief Executive Officer (CEO) of the Danish company Coloplast, where he will take office in 2026. His career has primarily been in international health and medical technology groups, where he has worked with strategic management, commercial development, and global expansion. ⸻ Background and Education Wood is educated in both law and business: • Bachelor of Laws from Carleton University in Ottawa • MBA from Queen’s University The combination of legal and commercial education is relatively common among leaders in regulated industries such as medtech and pharma, where an understanding of regulatory requirements, healthcare systems, and global markets is important. ⸻ Career in the Medtech Industry Wood has worked for more than two decades in the international health industry. A large part of his career has been with Johnson & Johnson, one of the world's largest healthcare groups. Johnson & Johnson MedTech At Johnson & Johnson, he held a number of leadership roles, including: • Head of the MedTech business in Europe, Middle East, and Africa (EMEA) • Responsibility for large portfolios within surgery and medical devices • Leadership of organizations with thousands of employees across many countries Hem also worked in the Ethicon division, which produces surgical instruments, sutures, and robotic technology for operations. Mölnlycke Health Care Before some of his later roles at Johnson & Johnson, he was also a leader at Mölnlycke Health Care, a Swedish company known for wound care products and surgical equipment. Here he worked with international commercial development and market strategy. ⸻ Role in the Industry In addition to his corporate roles, Wood has also had influence in the industry through the organization MedTech Europe, where he has served as Vice-Chairman. The organization represents European manufacturers of medical devices and works with regulation, innovation, and health policy in the EU. ⸻ CEO for Coloplast When he was chosen as CEO for Coloplast, the board pointed to several reasons: • Extensive international experience in medical technology • Proven ability to drive global growth and commercial scaling • Experience with both hospital technology and chronic patient products Coloplast is a global company that produces products for, among others: • ostomy • continence • wound care • urology The company has its headquarters in Denmark, but the majority of its revenue comes from international markets. Wood is therefore expected to: • strengthen Coloplast's global growth, especially in the USA • develop new medical products and technologies • continue the company's focus on specialized patient groups
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 53 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 27 | - | - |
Ylin
467,5VWAP
Alin
459,4VaihtoMäärä
50,4 108 713
VWAP
Ylin
467,5Alin
459,4VaihtoMäärä
50,4 108 713
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
18,00 DKK/osake
Viimeisin osinko
4,96%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenColoplast is a quality stock with high margins but also a very high PE, which demands high growth.. A growth they haven't exactly had, and not least, they have faced particularly challenging conditions in the Chinese market. Conversely, demographics work for them. The world's population is getting older. This increases the need for: catheters ostomy products wound care This provides (should provide) long-term structural growth. So more than tempting to start buying up, the dividend is 5 pct., but it is certainly not cheap on key figures despite a loooong and significant share price drop.
- ·5 t sittenIs it conceivable Coloplast will cut the dividend?
- ·6 t sittencouldn't really detect much enthusiasm???
- ·6 t sittenChatGPT: Gavin Wood Gavin Wood is a Canadian business leader in the global medical technology industry (medtech). He has been appointed as the new Chief Executive Officer (CEO) of the Danish company Coloplast, where he will take office in 2026. His career has primarily been in international health and medical technology groups, where he has worked with strategic management, commercial development, and global expansion. ⸻ Background and Education Wood is educated in both law and business: • Bachelor of Laws from Carleton University in Ottawa • MBA from Queen’s University The combination of legal and commercial education is relatively common among leaders in regulated industries such as medtech and pharma, where an understanding of regulatory requirements, healthcare systems, and global markets is important. ⸻ Career in the Medtech Industry Wood has worked for more than two decades in the international health industry. A large part of his career has been with Johnson & Johnson, one of the world's largest healthcare groups. Johnson & Johnson MedTech At Johnson & Johnson, he held a number of leadership roles, including: • Head of the MedTech business in Europe, Middle East, and Africa (EMEA) • Responsibility for large portfolios within surgery and medical devices • Leadership of organizations with thousands of employees across many countries Hem also worked in the Ethicon division, which produces surgical instruments, sutures, and robotic technology for operations. Mölnlycke Health Care Before some of his later roles at Johnson & Johnson, he was also a leader at Mölnlycke Health Care, a Swedish company known for wound care products and surgical equipment. Here he worked with international commercial development and market strategy. ⸻ Role in the Industry In addition to his corporate roles, Wood has also had influence in the industry through the organization MedTech Europe, where he has served as Vice-Chairman. The organization represents European manufacturers of medical devices and works with regulation, innovation, and health policy in the EU. ⸻ CEO for Coloplast When he was chosen as CEO for Coloplast, the board pointed to several reasons: • Extensive international experience in medical technology • Proven ability to drive global growth and commercial scaling • Experience with both hospital technology and chronic patient products Coloplast is a global company that produces products for, among others: • ostomy • continence • wound care • urology The company has its headquarters in Denmark, but the majority of its revenue comes from international markets. Wood is therefore expected to: • strengthen Coloplast's global growth, especially in the USA • develop new medical products and technologies • continue the company's focus on specialized patient groups
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 53 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 27 | - | - |
Ylin
467,5VWAP
Alin
459,4VaihtoMäärä
50,4 108 713
VWAP
Ylin
467,5Alin
459,4VaihtoMäärä
50,4 108 713
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 113 848 | 113 848 | 0 | 0 |